Evidence map›Paper›PMID 25043973›Full record

ArticleArchives of biochemistry and biophysics2014

MicroRNA-340 as a modulator of RAS-RAF-MAPK signaling in melanoma.

Ashley M Poenitzsch Strong, Vijayasaradhi Setaluri, Vladimir S Spiegelman

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of biochemistry and biophysics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 61 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Updates on Tumor Biology in Vestibular Schwannoma.Otolaryngologic clinics of North America · 2023
    Review
  8. A novel prognostic biomarker:Translational cancer research · 2023
    Article
  9. Review
  10. Interplay between K-RAS and miRNAs.Trends in cancer · 2022
    Review
  11. Article
  12. Review
  13. miR-340: A multifunctional role in human malignant diseases.International journal of biological sciences · 2021
    Review
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Ashley M Poenitzsch StrongDepartment of Dermatology, University of Wisconsin-Madison, School of Medicine and Public Health, 1300 University Avenue, Madison, WI 53706, United States; Molecular and Environmental Toxicology Center, University of Wisconsin-Madison, School of Medicine and Public Health, 1300 University Avenue, Madison, WI 53706, United States.
Vijayasaradhi SetaluriDepartment of Dermatology, University of Wisconsin-Madison, School of Medicine and Public Health, 1300 University Avenue, Madison, WI 53706, United States; Molecular and Environmental Toxicology Center, University of Wisconsin-Madison, School of Medicine and Public Health, 1300 University Avenue, Madison, WI 53706, United States; UW Carbone Cancer Center, University of Wisconsin-Madison, School of Medicine and Public Health, 600 Highland Avenue, Madison, WI 53792, United States.
Vladimir S SpiegelmanDepartment of Dermatology, University of Wisconsin-Madison, School of Medicine and Public Health, 1300 University Avenue, Madison, WI 53706, United States; Molecular and Environmental Toxicology Center, University of Wisconsin-Madison, School of Medicine and Public Health, 1300 University Avenue, Madison, WI 53706, United States; UW Carbone Cancer Center, University of Wisconsin-Madison, School of Medicine and Public Health, 600 Highland Avenue, Madison, WI 53792, United States. Electronic address: spiegelman@dermatology.wisc.edu.
University of Wisconsin–Madison · USUniversity of Wisconsin Carbone Cancer Center · US

Funding

Molecular & Environmental Toxicology Pre-& Postdoctoral Training ProgramT32ES007015 · NIEHS · UNIVERSITY OF WISCONSIN-MADISON · PI CHRISTOPHER A BRADFIELD · 1985 to 2026
$11.5M
RNA-binding protein CRD-BP in melanocyte biologyR01AR063361 · NIAMS · UNIVERSITY OF WISCONSIN-MADISON · PI SPIEGELMAN, VLADIMIR S. · 2013 to 2017
$1.6M
NIAMS NIH HHS AR063361NIAMS NIH HHS R01 AR063361NIEHS NIH HHS ES007015NIEHS NIH HHS T32 ES007015
6 · The paper itself

Abstract

microRNA (miRNA)-dependent regulation of gene expression is increasingly linked to development and progression of melanoma. In this study we evaluated the functions of miR-340 in human melanoma cells. Here, we show that miR-340 inhibits the tumorigenic phenotype of melanoma cells. We also found that miR-340 regulates RAS-RAF-Mitogen Activated Protein Kinase (MAPK) signaling by modulating the expression of multiple components of this pathway. Given the importance of MAPK signaling in melanoma, these results provide further insight into the pathogenesis of melanoma.

Indexed as

Cell Line, TumorGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansMAP Kinase Signaling SystemMelanomaMicroRNAsMutationPhenotyperaf Kinasesras ProteinsSignal TransductionMicroRNAsMIRN340 microRNA, humanraf Kinasesras ProteinsInvasionMAPKMelanomamicroRNAmiR-340ProliferationRAFRASTumor suppressor

Identifiers

PMID25043973
PMCPMC4221550
OpenAlexW1989696440

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.